


Adenovirus hexon modification for enhanced vaccine vectors

A vaccine platform technology that introduces large antigen or peptide insertions into ChAdOx2 adenoviral hexon regions, including a newly identified HVR7 site. The approach enables surface display of epitopes and protein-coupling tags, enhancing antibody responses while maintaining transgene delivery and T-cell immunogenicity.

Applications: Vaccines, gene therapy, cancer immunotherapy



Features	Benefits
Enables surface presentation of epitopes	Expands antigen design flexibility for vaccine developers
Novel HVR7 hexon insertion site for antigen display	Supports large peptide insertions in multiple hexon regions
Expands antigen design flexibility for vaccine developers	Reduces reliance on separate nanoparticle or VLP platforms
Maintains adenoviral vector infectivity and transgene delivery	Applicable to infectious disease, cancer, and gene therapy strategies

Patented and Available for

- Co-development

- Consulting
 - Licensing
-

To find out more, contact enquiries@innovation.ox.ac.uk and quote the project number.

The above information is provided 'as is' without conditions or warranties. Oxford University Innovation makes no representation and gives no warranty that it is the owner of the intellectual property rights in the technology described. © Oxford University Innovation Ltd 2026, Buxton Court, 3 West Way, Oxford, OX2 0JB.